Conversation: Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)

Agreement with Grünenthal for rights to Nexium in Europe and Vimovo worldwide (ex-US)

AstraZeneca has agreed to divest the prescription medicine rights to Nexium (esomeprazole) in Europe, as well as the global rights (excluding the US and Japan) to Vimovo (naproxen/esomeprazole) to Grünenthal. The medicines are outside AstraZeneca's three main therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. Nexium has lost compound patent protection in the majority of global markets. Vimovo is patent protected in most European markets until 2025.Nexium, a proton pump inhibitor developed by AstraZeneca, helps to reduce the amount of acid produced by the stomach in patients with gastrointestinal reflux conditions and ulcers. It has a number of indications, including the prevention and treatment of gastric ulcers induced by pain-relieving non-steroidal anti-inflammatory drugs (NSAIDs).Read more: http://www.worldpharmanews.com/astrazeneca/4594-agreement-with-gruenenthal-for-rights-to-nexium-in-europe-and-vimovo-worldwide-ex-us